RxDoctor Payments Data

Thejaswini Kaggere, MD

Nephrology · Goldsboro, NCNPI 1659532992

Payments from drug & device makers

$1,235in general payments, 2019–2025

Across 57 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$296
  • Otsuka America Pharmaceutical, Inc.$195
  • Amgen$143
  • Fresenius USA Marketing, Inc.$78
  • Calliditas Therapeutics US Inc.$66
  • Bayer$62
  • plus $396 from 12 others

What the payments were for

  • Food & beverage$1,20598%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,235 in reported general payments places this provider in the 45th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$172,940
Medicare patients
248
Services billed
2,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol249$168,030
JardianceEmpagliflozin58$35,078
VelphoroSucroferric Oxyhydroxide12$24,786
KerendiaFinerenone19$11,950
Sevelamer Carbonate31$3,010
Calcium Acetate29$2,889
Calcitriol82$1,069
Amlodipine Besylate140$691
Gentamicin Sulfate13$609
Metoprolol Succinate58$530
Losartan Potassium118$523
Midodrine Hcl15$474
Furosemide72$306
Hydroxyzine Hcl12$305
Hydralazine Hcl35$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$296$168,030249 claims
Boehringer IngelheimJardiance$41$35,07858 claims
Fresenius USA Marketing, Inc.Velphoro$78$24,78612 claims
BayerKerendia$62$11,95019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Goldsboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →